USPTO serial 79307984
EXPLORNA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 14, 2022
- Examiner
- LEE, REBECCA ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EXPLORNA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
PL
Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
PL
Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
PL
Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Geza Ziegler
Geza Ziegler ZIEGLER IP LAW GROUP LLC.3135 Easton TpkeSHU iHUB, W256Fairfield, CT 06825Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Human vaccine preparations; vaccine adjuvants; medicinal preparations for the treatment of cancer, infectious diseases, metabolic diseases, allergic diseases, autoimmune diseases, cardiovascular diseases, diseases of the nervous system, diseases of gastrointestinal system, diseases of respiratory system, diseases of skin, diseases of secretory systems, diseases of bones and joints, diseases of hematopoietic system and animal diseases; nucleic acid sequences and chemical reagents for medical and veterinary purposes | ACTIVE | — |
| 042 | Research and development of mRNA therapeutics; biochemical research and development; research and development of vaccines and medicines; pharmaceutical products development; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; working on and evaluation of chemical syntheses | ACTIVE | — |
| 044 | Medical analysis for the diagnosis and treatment of persons; Medical analysis services in the nature of RNA or DNA analysis for the diagnosis and prognosis of cancer; consultancy services relating to health care; medical services in the fields of oncology, dentistry, ophthalmology, transplant medicine, infectious diseases, metabolic diseases, allergic diseases, autoimmune diseases, cardiovascular diseases, diseases of the nervous system, diseases of gastrointestinal system, diseases of respiratory system, diseases of skin, diseases of secretory systems, diseases of bones and joints, and diseases of hematopoietic system | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
- Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
- Other trademarks owned by EXPLORNA THERAPEUTICS SPÓLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EXPLORNA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 14, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 6, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Oct 6, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Sep 14, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 27, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 14, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 14, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 29, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 29, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 27, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 10, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 9, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 9, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 22, 2022 | ALIE | ASSIGNED TO LIE | — |
| Feb 22, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 21, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 21, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 21, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Feb 20, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 20, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 20, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 28, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 28, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 28, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 25, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 30, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 30, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 16, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 15, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 13, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 7, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 1, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |